Endometriosis: From Genes to Global Gaps

Recent key publications
 

Non-invasive blood tests for earlier diagnosis and treatment of endometriosis. 
Reprod Immunol 2025; 169:104521. Sadeghzadeh Oskouei B, Asadi Z, Jahanban Esfahlan R.

Link to full article: http://www.ncbi.nlm.nih.gov/pubmed/?term=40121746

The diagnosis of endometriosis remains clinically challenging due to its chronic progression, heterogeneous clinical presentations, and the absence of effective non-invasive diagnostic methods. These factors frequently lead to diagnostic delays and compromised patient care. However, emerging molecular diagnostic technologies are revolutionizing the approach to early detection and individualized treatment strategies. Key innovations include the discovery of circulating biomarkers, exosomal microRNAs, and advanced biosensor platforms that promise to transform clinical practice.

The development of blood-based and menstrual fluid diagnostic assays, combined with comprehensive epigenetic and genetic profiling techniques, represents a paradigm shift away from traditional invasive diagnostic procedures. These technological advances position the medical community to address longstanding diagnostic limitations and improve patient outcomes significantly.

This review consolidates current research findings and technological innovations, providing clinicians and researchers with an in-depth analysis of evolving diagnostic and therapeutic approaches for endometriosis, incorporating the most recent scientific developments as of 2025.

N6-methyladenosine methylation regulators can serve as potential biomarkers for endometriosis related infertility. 
Biomol Biomed 2025; 25:1540-1552. He Y, Ding J, Bai T et al.

Link to full article: http://www.ncbi.nlm.nih.gov/pubmed/?term=39739380

Infertility in women with endometriosis continues to challenge both clinicians and researchers, with late diagnosis and unreliable non-invasive testing preventing optimal timing for effective therapeutic interventions. Recent breakthroughs in epigenetic studies have highlighted the role of N6-methyladenosine (m6A) methylation in reproductive diseases, yet the molecular mechanisms linking m6A regulatory elements to endometriosis-associated infertility are not completely understood. This research performs an extensive multi-omics investigation, merging bulk and single-cell transcriptomic techniques, to identify essential m6A regulators—notably HNRNPA2B1 and HNRNPC—as potential diagnostic biomarkers. These results contribute important knowledge about immune and endocrine pathways in endometriosis, furthering current work to create personalized treatment approaches for women's fertility disorders.

Endometriosis: Challenges in Clinical Molecular Diagnostics and Treatment. 
Int J Mol Sci 2025; 26. Rosendo-Chalma P, Díaz-Landy EN, Antonio-Véjar V et al.

Link to full article: http://www.ncbi.nlm.nih.gov/pubmed/?term=40362218

Endometriosis continues to be a widespread but frequently undiagnosed gynaecological condition, impacting roughly 10% of women of childbearing age worldwide, with diagnosis typically delayed by 4–11 years due to vague symptoms and dependence on invasive diagnostic procedures. Recent developments in molecular testing, including epigenetic alterations and non-coding RNA analysis, present encouraging opportunities for non-invasive identification and individualized treatment approaches. This review consolidates existing understanding of disease mechanisms, biomarker combinations, and treatment advances, filling important knowledge gaps in clinical care. Given the increasing focus on personalized medicine and the WHO's 2023 emphasis on endometriosis, this article delivers a relevant, thorough examination crucial for researchers and healthcare providers seeking to enhance diagnostic precision and patient care.

Genome-wide analyses identify 25 infertility loci and relationships with reproductive traits across the allele frequency spectrum. 
Nat Genet 2025; 57:1107-1118. Venkatesh SS, Wittemans LBL, Palmer DS et al.

Link to full article: http://www.ncbi.nlm.nih.gov/pubmed/?term=40229599

Infertility impacts one in six couples worldwide, but the genetic factors underlying this condition remain largely unclear despite progress in genomic studies. This extensive genome-wide meta-analysis examined 42,629 female and 10,886 male infertility cases, discovering 25 previously unknown genetic locations and clarifying their connections to reproductive hormones and disorders including endometriosis and PCOS. Through combining common and rare genetic variant analyses across seven study groups, the results demonstrate minimal genetic similarity between infertility and obesity, contradicting established clinical beliefs. The study also reveals evidence of evolutionary selection pressure at infertility-risk genetic sites, providing fresh understanding of why these genetic variants persist in populations. These findings establish a fundamental basis for future research into the biological mechanisms and potential treatments for infertility.

Global, Regional and National Burden of Infertility due to Endometriosis: Results From the Global Burden of Disease Study 2021 and Forecast to 2044. 
Bjog 2025; 132:944-960. Chen Y, Liu C, Wang X et al.

Link to full article: http://www.ncbi.nlm.nih.gov/pubmed/?term=39996398

Endometriosis represents one of the primary causes of infertility, impacting approximately 10–15% of women of reproductive age worldwide, though its epidemiological impact and socio-demographic variations remain inadequately understood. This research utilizes extensive data from the Global Burden of Disease Study 2021 to examine temporal patterns, age-period-cohort influences, and international disparities in endometriosis-related infertility from 1990 to 2021, including forecasts through 2044. Recent progress in diagnostic methods and therapeutic options emphasizes the importance of comprehending these patterns to guide focused interventions. The results demonstrate substantial health disparities, especially in resource-limited environments, underscoring the essential need for policy modifications to tackle this expanding public health issue.

Risk factors for recurrent implantation failure as defined by the European Society for Human Reproduction and Embryology. 
Hum Reprod 2025; 40:1138-1147. Wang C, Lu Y, Ou M et al.

Link to full article: http://www.ncbi.nlm.nih.gov/pubmed/?term=40143620

Recurrent implantation failure (RIF) continues to pose a major obstacle in assisted reproductive technology (ART), with its complex underlying causes remaining poorly understood, despite recent progress in the field. While the 2023 ESHRE guidelines organized RIF classification by patient age, growing research indicates that other key factors, including anti-Müllerian hormone (AMH) levels and chronic endometritis, may serve as crucial determinants. This research utilizes machine learning methodology to identify and prioritize risk factors associated with RIF, demonstrating that AMH emerges as the most significant predictor, with endometrial disorders and body mass index (BMI) following as secondary factors. These results provide new perspectives on RIF diagnosis and treatment, filling important knowledge gaps in existing research while delivering practical information to enhance ART success rates. The findings highlight the importance of adoptinadopting a comprehensive, multi-factor framework for RIF evaluation.